Diagnostics

Diagnostics, a child sector within Superscout's Healthcare category, encompasses the technologies and platforms that detect, identify, and monitor diseases and health conditions, including in vitro diagnostics (IVD), point-of-care testing, molecular diagnostics, liquid biopsy, companion diagnostics, and AI-powered diagnostic interpretation. With 20 funders actively investing in diagnostics startups tracked in Superscout's database, the sector draws capital from life science venture funds, healthcare-focused growth equity firms, and corporate ventures of diagnostic and pharmaceutical companies.

The diagnostics investment thesis is powered by two converging trends: the shift toward precision medicine (where treatment decisions are guided by diagnostic data rather than population averages) and the AI revolution in diagnostic interpretation (where machine learning models can detect patterns in medical images, genomic data, and biomarker panels that exceed human expert accuracy). The global diagnostics market exceeds $80 billion annually and is growing at 6-8% per year, with the fastest growth in liquid biopsy, point-of-care molecular testing, and AI-powered pathology.

Superscout's stage data shows 15 funders (75%) at seed, 9 (45%) at pre-seed, 12 (60%) at Series A, 8 (40%) at Series B, and 10 (50%) at growth equity. The median minimum check is $500,000, median maximum is $42.5 million, and the 75th percentile reaches $81.25 million. The extremely high growth equity ratio (50%) and very large check sizes reflect the capital intensity and regulatory complexity of diagnostics: developing a diagnostic test through clinical validation, FDA clearance or approval, and commercial launch requires significant investment, but successful diagnostics generate high-margin recurring revenue from consumables and test volume.

Liquid biopsy, which detects cancer and other diseases through simple blood draws rather than invasive tissue biopsies, represents the most exciting and rapidly funded category. Companies like Grail (multi-cancer early detection), Guardant Health (cancer genotyping), and Foundation Medicine (comprehensive genomic profiling) have demonstrated the commercial potential, and the next generation of liquid biopsy companies is expanding into earlier-stage cancer detection, treatment monitoring, and non-oncology applications.

For diagnostics founders, the 2025-2026 funding environment rewards companies with clinical data demonstrating sensitivity and specificity, clear regulatory strategy (LDT, 510(k), PMA, or de novo pathway), and reimbursement visibility from CMS or commercial payers.